Patients experienced a 42% improvement in range of motion from
baseline.

Patients exhibited a high rate of satisfaction with the treatment.

Cartiva SCI is intended to treat painful arthritis at the base of the
great toe---known as hallux rigidus --- the most common arthritic
condition in the foot. The current standard of care fuses the arthritic
joint bones with screws and plates. While effective at eliminating pain,
it permanently prevents movement of the joint.

Cartiva SCI is a biocompatible polymer implant designed to have physical
properties similar to articular cartilage. Damaged cartilage is replaced
with a small Cartiva SCI implant that provides a compressible, durable,
low-friction surface.

Cartiva SCI received Food and Drug Administration (FDA) premarket
approval in July 2016, the first and only synthetic cartilage device
approved by FDA.

The paper’s lead author, Timothy R. Daniels, M.D., FRCSC, Full
Professor, University of Toronto and Head, Division of Orthopaedic
Surgery, St. Michael's Hospital, said “These clinical results are
consistent with what I have seen in my own practice. Pain and functional
outcomes improved significantly, and 96% of the patients said they would
choose to undergo the procedure again.”

“Cartiva SCI has been used commercially outside the United States for
nearly l5 years, and publication of its long-term durability in this
prestigious, peer-reviewed journal is another key milestone,” said Tim
Patrick, president and CEO, Cartiva, Inc. “We will continue adding to
the unparalleled, Level 1 clinical evidence of Cartiva SCI as a
motion-preserving alternative to joint fusion.”

About Cartiva, Inc.

Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative
solutions for patients with cartilage damage and osteoarthritis.
Cartiva’s venture investors include New Enterprise Associates and
Windham Venture Partners. Additional information is available on the
company’s website at www.cartiva.net.

ALPHARETTA, Ga.--(EON: Enhanced Online News)--Cartiva, Inc. (Company), a developer of innovative products for treating cartilage damage and osteoarthritis, announced today that it has completed enr... more »